beta-interferon + cyclophosphamide + methotrexate + fluorouracil

This is a combination regimen consisting of four drugs: - Beta-interferon (commonly interferon beta-1a or beta-1b), an immunomodulatory cytokine used primarily in the treatment of multiple sclerosis, but also investigated for its anti-tumor and immunoregulatory properties. - Cyclophosphamide, an alkylating agent that crosslinks DNA, leading to cell death; widely used as chemotherapy and immunosuppressant. - Methotrexate, an antimetabolite and antifolate agent that inhibits dihydrofolate reductase, blocking DNA synthesis and cell replication; used in cancer therapy and autoimmune diseases. - Fluorouracil (5-FU), a pyrimidine analog antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis; commonly used in various cancers. The combination of cyclophosphamide, methotrexate, and fluorouracil is known as CMF—a well-established chemotherapy regimen for breast cancer[1][3][5]. The addition of beta-interferon is not standard but may be explored experimentally for synergistic effects on immune modulation or anti-tumor activity. Each drug acts via distinct mechanisms to target rapidly dividing cells or modulate immune responses.